Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 147

Results For "UST"

4813 News Found

Carbogen Amcis appoints Stephan Fritschi as CEO
People | February 04, 2025

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.


Akums combines two potent diabetes medicines for enhanced treatment efficacy
News | February 04, 2025

Akums combines two potent diabetes medicines for enhanced treatment efficacy

Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management


Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
News | February 04, 2025

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin


Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25
News | February 04, 2025

Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25

EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore


Jubilant Pharmova Q3 FY25 revenue up 9%
News | February 03, 2025

Jubilant Pharmova Q3 FY25 revenue up 9%

EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics


Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study
Clinical Trials | February 03, 2025

Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study

Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years


Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
News | February 03, 2025

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,


M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness
News | February 02, 2025

M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness

Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages


BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma
News | February 01, 2025

BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma

Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population


Biocon posts Q3 FY25 PAT at Rs. 25 Cr
News | January 31, 2025

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars